EUVIMEDEUVIMED entdecken
Crossref

Significance of Preoperative Chemotherapy and Chemoradiotherapy in Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer

Masaaki Murakawa, Rei Kanemoto, Tatsuya Kanai, Naohiko Matsushita, Mariko Kamiya, Satoshi Kobayashi, Makoto Ueno, Keisuke Kazama, Naoto Yamamoto, Takashi Ohshima, Aya Saito, Soichiro Morinaga

Anticancer Research · 2025

DOI: 10.21873/anticanres.17804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Masaaki Murakawa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan; m.murakawa@kcch.jp. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Chemoradiotherapy, Antineoplastic Combined Chemotherapy Protocols.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Multi-agent chemotherapy regimens have improved the survival of patients with pancreatic adenocarcinoma (PDAC). However, only a few studies have compared multi-regimen treatments with single-regimen followed by curative-intent resection. This study aimed to explore optimal treatment strategies and clarify the role of radiotherapy in borderline resectable PDAC (BRPC) and locally advanced PDAC (LAPC) treatment. PATIENTS AND METHODS: Consecutive patients who underwent pancreatectomy for PDAC at our institution between January 2013 and December 2022, diagnosed with BRPC and LAPC, and subjected to radical resection following preoperative chemotherapy or chemoradiotherapy were included in this study. We divided the cohort into preoperative multiple regimen (MR) and single regimen (SR) groups to compare survival. RESULTS: Of the 527 patients with PDAC, 68 who responded favorably to neoadjuvant therapy and subsequently underwent curative-intent or conversion resection were included in the analysis. In terms of overall survival, the 5-year survival rate was significantly higher in the MR group (80.8%) than in the SR group (20.3%). Multivariate analysis identified R0 resection, preoperative carbohydrate antigen 19-9 levels

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsChemoradiotherapyAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedPancreatectomyNeoadjuvant TherapyPrognosisRetrospective StudiesAdultTreatment OutcomePreoperative Care

Stichwörter der Autor:innen

Pancreatic cancerborderline resectable pancreatic cancerchemoradiotherapylocally-advanced pancreatic cancerprognosisresectability classification

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan; m.murakawa@kcch.jp.
  • Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
  • Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
  • Department of Surgery, Yokohama City University School of Medicine, Yokohama, Japan.

Zitieren

APA

Murakawa, M., Kanemoto, R., Kanai, T., Matsushita, N., Kamiya, M., Kobayashi, S., Ueno, M., Kazama, K., Yamamoto, N., Ohshima, T., Saito, A., & Morinaga, S. (2025). Significance of Preoperative Chemotherapy and Chemoradiotherapy in Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.17804

Vancouver

Murakawa M, Kanemoto R, Kanai T, Matsushita N, Kamiya M, Kobayashi S, et al. Significance of Preoperative Chemotherapy and Chemoradiotherapy in Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer. Anticancer Research. 2025. doi:10.21873/anticanres.17804

BibTeX
@article{Murakawa2025,
  author = {Murakawa, Masaaki and Kanemoto, Rei and Kanai, Tatsuya and Matsushita, Naohiko and Kamiya, Mariko and Kobayashi, Satoshi and Ueno, Makoto and Kazama, Keisuke and Yamamoto, Naoto and Ohshima, Takashi and Saito, Aya and Morinaga, Soichiro},
  title = {Significance of Preoperative Chemotherapy and Chemoradiotherapy in Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer},
  journal = {Anticancer Research},
  year = {2025},
  doi = {10.21873/anticanres.17804}
}
Kostenlos starten →